In "Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial," Márquez Loza et al. presented a patient who developed the Guillain-Barré syndrome (GBS) after being vaccinated in a COVID-19 vaccine clinical trial and highlighted the fact that this should not be considered a postvaccination complication, given that, by chance alone, 900–2,200 people can be expected to develop GBS within 6 weeks of a 1-dose vaccine and 1,500–3,700 people can be expected to develop GBS within 10 weeks of a 2-dose vaccine. Willer comments that although vaccines can increase the risk of GBS because of antibody production, they can also decrease the risk of GBS because of infection prevention. On behalf of the authors, Amato agrees that vaccines can reduce the risk of postinfection GBS in general but notes that a large epidemiologic cohort study found no causal relationship between COVID-19 and GBS and no evidence of molecular mimicry between any SARS-CoV-2 proteins and axonal or myelin proteins in human nerves. Amato recommends performance of large-scale epidemiologic studies and meta-analyses to better understand the relationship between COVID-19 vaccination and GBS.

在“COVID-19 疫苗临床试验的安慰剂和活性臂中的吉兰-巴雷综合征”中，Márquez Loza 等人。介绍了一名在 COVID-19 疫苗临床试验中接种疫苗后出现吉兰-巴雷综合征 (GBS) 的患者，并强调不应将这视为接种后并发症，因为仅偶然，900-2,200 人可以预计在接种 1 剂疫苗后的 6 周内会出现 GBS，而在接种 2 剂疫苗后的 10 周内，预计有 1,500-3,700 人会出现 GBS。Willer 评论说，虽然疫苗会因为产生抗体而增加 GBS 的风险，但它们也可以因为预防感染而降低 GBS 的风险。代表作者，Amato 同意疫苗总体上可以降低感染后 GBS 的风险，但指出一项大型流行病学队列研究发现 COVID-19 和 GBS 之间没有因果关系，也没有证据表明任何 SARS-CoV-2 蛋白与轴突或髓鞘蛋白之间存在分子模拟在人的神经中。Amato 建议进行大规模流行病学研究和荟萃分析，以更好地了解 COVID-19 疫苗接种与 GBS 之间的关系。